1. Home
  2. ARTL vs BGLC Comparison

ARTL vs BGLC Comparison

Compare ARTL & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$3.35

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$2.02

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARTL
BGLC
Founded
2011
2017
Country
United States
Malaysia
Employees
7
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
5.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ARTL
BGLC
Price
$3.35
$2.02
Analyst Decision
Hold
Analyst Count
2
0
Target Price
N/A
N/A
AVG Volume (30 Days)
502.4K
2.6K
Earning Date
05-13-2026
04-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.78
EPS
N/A
N/A
Revenue
N/A
$7,424,911.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$1.92
52 Week High
$28.60
$15.19

Technical Indicators

Market Signals
Indicator
ARTL
BGLC
Relative Strength Index (RSI) 39.23 38.66
Support Level $3.05 $1.92
Resistance Level $3.67 $2.73
Average True Range (ATR) 0.45 0.05
MACD -0.25 -0.01
Stochastic Oscillator 5.57 25.39

Price Performance

Historical Comparison
ARTL
BGLC

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: